Carbon fiber‐reinforced silicon carbide (C/SiC) composites have the potential to be utilized in many high‐temperature structural applications, particularly in aerospace. However, the susceptibility of the carbon fibers to oxidation has hindered the composite's use in long‐term reusable applications. In order to identify the composites limitations, fundamental oxidation studies were conducted to determine the effects of such variables as temperature, environment, and stress. The systematic studies first looked at the oxidation of the plain, uncoated carbon fiber, then when fiber was utilized within a C/SiC composite, and finally when a stress was applied to the C/SiC composite (stressed oxidation). The first study, oxidation of just the carbon fibers, showed that the fiber oxidation kinetics occurs in two primary regimes: chemical reaction control and diffusion control. The second study, oxidation of the C/SiC composite, showed the self‐protecting effects from the SiC matrix at elevated temperatures when the composite was not stressed. The final study, stressed oxidation of the C/SiC composite, more closely simulated application conditions in which the material is expected to encounter thermal and mechanical stresses. The applied load and temperature will affect the openings of the as‐fabricated cracks, which are an unavoidable characteristic of C/SiC composites. The main objective of the paper was to determine the oxidation kinetic regimes for the oxidation of carbon fibers in a cracked silicon carbide matrix under stressed and unstressed conditions. The studies help to provide insights in to the protective approaches, that could be used to prevent oxidation of the fibers within the composite.
Although still commonly used in clinical practice to screen and diagnose prostate cancer, there are numerous weaknesses of prostate-specific antigen (PSA) testing, including lack of specificity and the inability to distinguish between aggressive and indolent cancers. A promising prostate cancer biomarker, alpha-methylacyl-CoA racemase (AMACR), has been previously demonstrated to distinguish cancer from healthy and benign prostate cells with high sensitivity and specificity. However, no accurate clinically useful assay has been developed. This study reports the development of a single use, disposable biosensor for AMACR detection. Human blood samples were used to verify its validity, reproducibility and reliability. Plasma samples from 9 healthy males, 10 patients with high grade prostatic intraepithelial neoplasia (HGPIN), and 5 prostate cancer patients were measured for AMACR levels. The average AMACR levels in the prostate cancer patients was 10 fold higher (mean(SD) = 0.077 (0.10)) than either the controls (mean(SD) = 0.005 (0.001)) or HGPIN patients (mean(SD) = 0.004 (0.0005)). At a cutoff of between 0.08 and 0.9, we are able to achieve 100% accuracy in separating prostate cancer patients from controls. Our results provide strong evidence demonstrating that this biosensor can perform as a reliable assay for prostate cancer detection and diagnosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.